Balyasny Asset Management’s Cardlytics CDLX Stock Holding History

Balyasny Asset Management’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-17,386	Closed	-$1.43M	–	2772
2024 Q2	$1.43M	Buy	17,386 +4,605	+36%	+$498K	﹤0.01%	1655
2024 Q1	$1.85M	Buy	12,781 +971	+8%	+$82K	﹤0.01%	1557
2023 Q4	$1.09M	Buy	+11,810	New	+$1.2M	﹤0.01%	1651
2022 Q3	–	Sell	-1,305	Closed	-$291K	–	2881
2022 Q2	$291K	Buy	+1,305	New	+$437K	﹤0.01%	2104
2022 Q1	–	Sell	-1,169	Closed	-$772K	–	2502
2021 Q4	$772K	Buy	+1,169	New	+$894K	﹤0.01%	1518
2018 Q4	–	Sell	-4,735	Closed	-$1.19M	–	1435
2018 Q3	$1.19M	Buy	4,735 +2,015	+74%	+$434K	0.01%	1134
2018 Q2	$592K	Buy	2,720 +220	+9%	+$40.7K	﹤0.01%	1293
2018 Q1	$366K	Buy	+2,500	New	+$423K	﹤0.01%	1549

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return

WPM

Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return

BCM

Brightlight Capital Management Westport, Connecticut $101M AUM 23.43% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Balyasny Asset Management's CDLX Position: Q3 2024 in Review

Balyasny Asset Management sold out of Cardlytics (CDLX) in Q3 2024, closing a stake of 17,386 shares — an estimated $1.43M sold.

Balyasny Asset Management first reported a position in CDLX in Q1 2018 and held it in 8 quarters. The position peaked at $1.85M in Q1 2024. 111 funds tracked by Wall St. Rank hold CDLX as of Q3 2024.

Balyasny Asset Management reported no remaining Cardlytics position as of Q3 2024 after selling out during the quarter.
Balyasny Asset Management sold 17,386 Cardlytics shares in Q3 2024, an estimated $1.43M.
Balyasny Asset Management first reported a position in Cardlytics in Q1 2018 and held it in 8 quarters.
Balyasny Asset Management's Cardlytics position peaked at $1.85M in Q1 2024.
111 funds tracked by Wall St. Rank held Cardlytics as of Q3 2024.

Based on Balyasny Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.